Merck Life Science has entered into a strategic partnership with Aragen, an R&D and manufacturing solutions provider in the life sciences industry. The collaboration focuses on expediting the development of monoclonal antibodies (mAbs) and other novel modalities.
The Memorandum of Understanding (MoU) was officially signed by Aditya Sharma, Head of Process Solutions for the India Region at Merck Life Science, and Subodh Deshmukh, CEO of Aragen Bioscience.
Click here to connect with us on WhatsApp
Under this MoU, Merck Life Science will supply equipment and technologies to Aragen, facilitating a more efficient clinical-to-commercial process timeline. This collaboration is expected to streamline the development of novel molecules and support scale-up efforts for emerging biotechnology startups in India.